VXRT:OTCMKTS
Vaxart Inc
$0.44
arrow_upward
+1.47%(+0.0064) 1D
Oct 9, 1:20:03 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for VXRT...
Open
$0.44
High
$0.45
Low
$0.43
Mkt. cap
108.17M
Avg. vol.
265.13K
Volume
160.21K
P/E ratio
2.70
52-wk high
$0.84
52-wk low
$0.30
EPS
$0.16
Beta
1.05
Shares outstanding
242.84M
No. of employees
65
Open
$0.44
High
$0.45
Low
$0.43
Mkt. cap
108.17M
Avg. vol.
265.13K
Volume
160.21K
P/E ratio
2.70
52-wk high
$0.84
52-wk low
$0.30
EPS
$0.16
Beta
1.05
Shares outstanding
242.84M
No. of employees
65
News stories
From web sources and news partners
Profile
Vaxart, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines administered using temperature-stable tablets that can be stored and shipped without refrigeration, eliminating the need for needle injection. Its development programs for oral vaccine delivery include prophylactic, enteric-coated tablet vaccines for inhibiting norovirus, seasonal influenza, respiratory syncytial virus, and human papillomavirus. It was founded in 2004 by Sean Tucker. Originally incorporated as West Coast Biologicals, Inc. in California in 2004, the company later changed its name to Vaxart, Inc. in July 2007, after reincorporating in Delaware. A significant development in the company's history was the reverse merger with Aviragen Therapeutics, Inc. on February 13, 2018, which led to Vaxart becoming a wholly owned subsidiary of Aviragen. Post-merger, the company continued as Vaxart, Inc.
Vaxart's development portfolio includes a range of oral vaccines targeting infectious diseases such as norovirus, COVID-19, and seasonal influenza, as well as therapeutic vaccines like those targeting HPV. Wikipedia
About Vaxart Inc
CEO-
Employees65
FoundedMar 2004
HeadquartersSouth San Francisco, California, United States
SectorBiotechnology
Websitevaxart.com